Small studies: Strengths and limitations

European Respiratory Journal

Volumn 32, Issue 5, 2008, Pages 1141-1143

  Hackshaw, A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATTRIBUTABLE RISK; BIOASSAY; CLINICAL RESEARCH; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DISEASE MARKER; EDITORIAL; HAZARD RATIO; MULTIVARIATE ANALYSIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK; RISK FACTOR; SAMPLE SIZE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STRENGTH;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; DIET THERAPY; HUMANS; LUNG NEOPLASMS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; RISK FACTORS; SAMPLE SIZE; SMALL CELL LUNG CARCINOMA; SMOKING; THALIDOMIDE; TIME FACTORS; WEIGHT LOSS;

EID: 58849111736     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00136408     Document Type: Editorial

References (5)

1. Pocock SJ, ed. Clinical Trials: A Practical Approach. New York, John Wiley Sons, 1983.
2. Machin D, Campbell MJ, Fayers PM, Pinol APY, eds. Sample Size Tables for Clinical Studies. 2nd Edn. Oxford, Blackwell Science, 1997.
3. Altman DG, Bland JM. Absence of evidence is not evidence of absence. BMJ 1995; 311: 485.
4. Lee SM, James L, Buchler T, Snee M, Ellis P, Hackshaw A. Phase II trial of thalidomide with chemotherapy and as a maintenance therapy for patients with poor prognosis small-cell lung cancer. Lung Cancer 2008; 59: 364-368.
5. Lee SM, Rudd RM, Woll PJ, et al. Two randomised phase III, double blind, placebo controlled trials of thalidomide in patients with advanced non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). J Clin Oncol 2008; 26: 8045.